These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2073105)

  • 1. Pharmacokinetics of cefprozil in infants and children.
    Sáez-Llorens X; Shyu WC; Shelton S; Kumiesz H; Nelson J
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2152-5. PubMed ID: 2073105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excretion of cefprozil into human breast milk.
    Shyu WC; Shah VR; Campbell DA; Venitz J; Jaganathan V; Pittman KA; Wilber RB; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):938-41. PubMed ID: 1510416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antacid on the bioavailability of cefprozil.
    Shyu WC; Wilber RB; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):962-5. PubMed ID: 1510420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.
    Shyu WC; Shah VR; Campbell DA; Wilber RB; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Sep; 32(9):798-803. PubMed ID: 1430299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.
    Shukla UA; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Aug; 32(8):725-31. PubMed ID: 1487562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1204-9. PubMed ID: 2393282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of cefprozil into tonsillar and adenoidal tissues.
    Shyu WC; Reilly J; Campbell DA; Wilber RB; Barbhaiya RH
    Antimicrob Agents Chemother; 1993 May; 37(5):1180-3. PubMed ID: 8517711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute bioavailability of cefprozil after oral administration in beagles.
    Barbhaiya RH; Wang L; Shyu WC; Pittman KA
    Antimicrob Agents Chemother; 1992 Mar; 36(3):687-9. PubMed ID: 1622187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment.
    Shyu WC; Wilber RB; Pittman KA; Garg DC; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):372-6. PubMed ID: 2037711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Laboratory and clinical studies of cefprozil in pediatric field].
    Nishimura T; Tabuki K; Aoki S; Takagi M
    Jpn J Antibiot; 1992 Nov; 45(11):1582-91. PubMed ID: 1494239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1210-3. PubMed ID: 2393283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of cefprozil into middle ear fluid of patients with otitis media.
    Shyu WC; Haddad J; Reilly J; Khan WN; Campbell DA; Tsai Y; Barbhaiya RH
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2210-2. PubMed ID: 7811050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overall clinical evaluation of cefprozil against infections in pediatric fields. Pediatric Study Group for Cefprozil].
    Fujii R; Meguro H; Tajima T; Shiraishi H; Abe T; Nakazawa S; Sato H; Niinou K; Matsumoto K; Sunakawa K
    Jpn J Antibiot; 1992 Nov; 45(11):1592-608. PubMed ID: 1494240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical studies on cefprozil granules in pediatrics].
    Nakazawa S; Sato H; Narita A; Nakazawa S; Suzuki H; Matsumoto K; Niinou K
    Jpn J Antibiot; 1992 Nov; 45(11):1514-25. PubMed ID: 1494234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
    Nicolau DP; Sutherland CA; Arguedas A; Dagan R; Pichichero ME
    Paediatr Drugs; 2007; 9(2):119-23. PubMed ID: 17407367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of LY163892 in infants and children.
    Nelson JD; Shelton S; Kusmiesz H
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1738-9. PubMed ID: 3252754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
    Cappelletty DM; Rybak MJ
    Antimicrob Agents Chemother; 1996 May; 40(5):1148-52. PubMed ID: 8723456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of time of administration and posture on the pharmacokinetics of cefprozil.
    Shyu WC; Gleason CR; Barbhaiya RH
    Clin Pharmacokinet; 1993 Sep; 25(3):237-42. PubMed ID: 8222462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.